Skip to main content

Cost-effective reimbursement analysis for medical technologies in Europe

Procedure coding, payment mechanism, reimbursement tariffs, policy, and HTA considerations in 20 EU countries

Learn more

White Paper: Health Economic Evidence Requirements for Medical Devices in Europe

Get insights from MTRC White Papers to discover health economic evidence requirements and best practices for market access in the EU5

Request free of charge
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

EU HTA Publication Digest: EU Joint Clinical Assessment: A Framework for Optimising Use with Cost-Effectiveness Decision-Making

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. 

In a recent publication, Johns et al. examined the practical implications of the EU Joint Clinical Assessment (JCA) for countries considering cost-effectiveness analyses. The authors showed that while JCA harmonises the appraisal of clinical effectiveness and safety, its exclusion of economic evaluation leads to potential misalignment with national processes. They noted that economic analyses remain fragmented due to diverse national PICOs, a divergence that increases the complexity of evidence synthesis and could necessitate reliance on indirect comparisons. The study emphasized that earlier exchange of national PICOs could improve alignment, strengthen the usefulness of JCA outputs, and ultimately support more consistent patient access.

Access the full-text article here.